UCB : announces U.S. FDA approval of RYSTIGGO (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis
UCB announces U.S. FDA approval of RYSTIGGO[®] (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis FDA approval of RYSTIGGO® (rozanolixizumab-noli) has been granted under...
Source: marketscreener.com